MedTrace Logo

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT00937352 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 896

Last updated 2013-12-20

No results posted yet for this study

Summary

The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.

Conditions

Interventions

DRUG

Bapineuzumab

0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years. 1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • JANSSEN Alzheimer Immunotherapy Research & Development, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
51 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States
  • Austria
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937352 on ClinicalTrials.gov